GleamWall
中文EN

PRME Prime Medicine, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1894562 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY55.3%
TTM net income YoY-2.7%
TTM EPS YoY18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,498.1%
Net margin-4,342.4%
FCF margin-3,607.4%
EBITDA margin-4,340.0%

Returns

ROE-146.8%
ROA-62.8%
ROIC (approx.)-2,278.6%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets64.7%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-12.1%
Payout ratio—
Capex / revenue97.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.63M$2.98M
R&D expense$160.64M$155.29M
SG&A expense$52.35M$50.16M
Operating income-$208.35M-$202.47M
Income tax$0$0
Net income-$201.14M-$195.88M
EBITDA-$201.03M-$196.34M
EPS (basic)-1.35-1.65
EPS (diluted)-1.35-1.65
Weighted avg. shares (diluted)148.76M118.60M
Balance sheet
Cash & equivalents$63.03M$196.54M
Short-term investments$114.65M—
Current assets$181.29M$211.89M
PP&E, net$20.57M$24.40M
Total assets$342.73M$297.51M
Current liabilities$37.45M$37.96M
Total liabilities$221.87M$144.36M
Shareholders' equity$120.87M$153.15M
Shares outstanding180.51M131.16M
Cash flow statement
Operating cash flow-$162.56M-$122.86M
Capital expenditure$4.53M$7.29M
Free cash flow-$167.09M-$130.16M
Investing cash flow-$108.76M$68.46M
Financing cash flow$151.51M$195.88M
Depreciation & amortization$7.32M$6.13M
Stock-based compensation$29.27M$26.07M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.